Constitutive NOS Production Is Modulated by Alzheimer's Disease Pathology Depending on APOE Genotype

Chiara Giuseppina Bonomi,Alessandro Martorana,Denise Fiorelli,Marzia Nuccetelli,Fabio Placidi,Nicola Biagio Mercuri,Caterina Motta

DOI: https://doi.org/10.3390/ijms25073725

IF: 5.6

2024-03-28

International Journal of Molecular Sciences

Abstract:Both the endothelial (eNOS) and the neuronal (nNOS) isoforms of constitutive Nitric Oxide Synthase have been implicated in vascular dysfunctions in Alzheimer's disease (AD). We aimed to explore the relationship between amyloid pathology and NO dynamics by comparing the cerebrospinal fluid (CSF) levels of nNOS and eNOS of 8 healthy controls (HC) and 27 patients with a clinical diagnosis of Alzheimer's disease and isolated CSF amyloid changes, stratified according to APOE ε genotype (APOE ε3 = 13, APOE ε4 = 14). Moreover, we explored the associations between NOS isoforms, CSF AD biomarkers, age, sex, cognitive decline, and blood–brain barrier permeability. In our cohort, both eNOS and nNOS levels were increased in APOE ε3 with respect to HC and APOE ε4. CSF eNOS inversely correlated with CSF Amyloid-β42 selectively in carriers of APOE ε3; CSF nNOS was negatively associated with age and CSF p-tau only in the APOE ε4 subgroup. Increased eNOS could represent compensative vasodilation to face progressive Aβ-induced vasoconstriction in APOE ε3, while nNOS could represent the activation of NO-mediated plasticity strategies in the same group. Our results confirm previous findings that the APOE genotype is linked with different vascular responses to AD pathology.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

This paper aims to explore the relationship between Alzheimer's disease (AD) pathology and the expression of nitric oxide synthase (NOS) in cerebrospinal fluid (CSF), considering the influence of apolipoprotein E (APOE) genotype. Specifically, the study focuses on the levels of two NOS isoenzymes, endothelial NOS (eNOS) and neuronal NOS (nNOS), in CSF and analyzes their relationship with amyloid-beta (Aβ) in CSF. Additionally, the study investigates the associations between NOS isoenzymes and AD biomarkers in CSF, age, gender, cognitive decline, and blood-brain barrier permeability.

The study found that in APOE ε3 carriers, CSF levels of eNOS and nNOS were higher than in healthy controls and APOE ε4 carriers. CSF eNOS levels were negatively correlated with CSF Aβ42, and this association was significant only in APOE ε3 carriers. In contrast, CSF nNOS was not significantly correlated with Aβ42, but in APOE ε4 carriers, nNOS was negatively correlated with age and CSF phosphorylated tau (p-tau) levels.

These results suggest that the APOE genotype plays a crucial role in modulating AD pathology and may influence the expression patterns of NOS isoenzymes in response to AD pathology. Specifically, the increase in eNOS in APOE ε3 carriers may be a compensatory mechanism against Aβ-induced vasoconstriction, while the increase in nNOS may reflect changes in neural plasticity.